Adverum Biotechnologies
在场
Adverum Biotechnologies 是一家在股票代码 ADVM (US) 下上市的公司。
高管
查看带有其 24 名主要高管的组织结构图
Adverum Biotechnologies 搜索最多的简介
- Laurent Fischer, President, Chief Executive Officer and Interim Ch...
- Scott Whitcup, Director
- James Scopa, Director
高管在Adverum Biotechnologies变化
- Romuald Corbau已作为Chief Scientific Officer加入公司 (新闻发布的2024一月29号).
- David Nicholson已作为Director加入公司 (新闻发布的2023十一月7号).
- Andrew Ramelmeier已作为Chief Technology Officer加入公司 (新闻发布的2023八月22号).
创建提醒
跟踪 Adverum Biotechnologies 的高管变动
生物技术
Adverum Biotechnologies 拥有 2,282 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
Adverum Biotechnologies 的最新新闻稿
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
- Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
- Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
- Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
- Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
- Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
- Adverum Biotechnologies, Inc. - Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society Back ButtonFilter Button
- Adverum Biotechnologies, Inc. - Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference Back ButtonFilter Button
- Adverum Biotechnologies, Inc. - Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights Back ButtonFilter Button
- View more press releases Close
通过电子邮件
